ClearPoint Neuro, Inc.
HealthcareNASDAQ:CLPT · NASDAQ Capital Market
-$0.40 today
Vol 0.44M · Avg 0.59M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$40.6M of revenue converted into -$29.1M of net income for the selected period. Gross margin is 61.8% and net margin is -70.8%, showing how much revenue survives after costs and taxes. EPS is $-1.01, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.0M +17.8% | $31.4M +31.0% | $24.0M +16.6% | $20.6M +26.1% | $16.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $14.3M +16.4% | $12.3M +18.6% | $10.3M +47.3% | $7.0M +35.6% | $5.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $22.7M +18.7% | $19.1M +40.5% | $13.6M +0.6% | $13.5M +21.6% | $11.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.4% +0.5pp | 60.9% +4.1pp | 56.8% -9.0pp | 65.8% -2.4pp | 68.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $13.9M +12.1% | $12.4M +5.8% | $11.7M +7.5% | $10.9M +17.4% | $9.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $33.0M +24.5% | $26.5M +8.7% | $24.4M +28.4% | $19.0M +24.7% | $15.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $46.9M +20.6% | $38.9M +7.8% | $36.1M +20.8% | $29.9M +21.9% | $24.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.2M +17.6% | $1.9M +30.6% | $1.5M +87.5% | $777.0K +12.3% | $692.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$20.9M -22.6% | -$17.0M +17.6% | -$20.6M -32.5% | -$15.6M -22.2% | -$12.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -56.4% -2.2pp | -54.2% +31.9pp | -86.1% -10.3pp | -75.8% +2.4pp | -78.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$24.2M -22.4% | -$19.7M +12.0% | -$22.4M -37.4% | -$16.3M -22.1% | -$13.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -65.4% -2.5pp | -62.9% +30.8pp | -93.7% -14.2pp | -79.5% +2.6pp | -82.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.2M +39.1% | $872.0K +125.9% | $386.0K | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.4M | $0 | $0 -100.0% | $81.0K -91.7% | $973.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.3M -258.8% | $832.0K +133.1% | $357.0K +446.6% | -$103.0K +90.1% | -$1.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$25.5M -34.7% | -$18.9M +14.4% | -$22.1M -34.4% | -$16.4M -14.1% | -$14.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -68.9% -8.7pp | -60.3% +32.0pp | -92.2% -12.2pp | -80.0% +8.4pp | -88.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $55.0K | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$25.5M -35.0% | -$18.9M +14.4% | -$22.1M -34.4% | -$16.4M -14.1% | -$14.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | -69.1% -8.8pp | -60.3% +32.0pp | -92.2% -12.2pp | -80.0% +8.4pp | -88.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -28.6% | -$1 +22.2% | -$1 -32.4% | -$1 +1.4% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -28.6% | -$1 +22.2% | -$1 -32.4% | -$1 +1.4% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $28.3M +4.8% | $27.0M +9.8% | $24.6M +1.8% | $24.2M +16.6% | $20.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $28.3M +4.8% | $27.0M +9.8% | $24.6M +1.8% | $24.2M +16.6% | $20.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
COMPASS Pathways plc
NASDAQ:CMPS
$1.16B
SI-BONE, Inc.
NASDAQ:SIBN
$683.87M
Surmodics, Inc.
SRDX
$614.51M
Cytek Biosciences, Inc.
NASDAQ:CTKB
$511.40M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
Orthofix Medical Inc.
NASDAQ:OFIX
$376.33M
SNDL Inc.
NASDAQ:SNDL
$369.44M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CLPT generate?
ClearPoint Neuro, Inc. (CLPT) reported $36.97M of revenue in fiscal 2025.
Is CLPT profitable?
ClearPoint Neuro, Inc. (CLPT) reported -$25,540,000.00 of net income, with a net margin of -69.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.